Products - Liver cancers | Topic | NICE

Showing 9 products

Date | Title

Status: PublishedRemove ‘Status: Published’ filter

Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2020
Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2022
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma (TA1090)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 August 2025
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 December 2018
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 October 2019
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 January 2019
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
3 July 2024
Published:
31 March 2021
SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)
Product type:
Guidance
Programme:
HealthTech guidance
Published:
29 August 2012
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 September 2017